Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Accrued research and development expenses

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept bcax:AccruedResearchAndDevelopmentExpenseCurrent.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Bicara Therapeutics's accrued research and development expenses?
Bicara Therapeutics (BCAX) reported accrued research and development expenses of $13.52M in Q1 2026.
How has Bicara Therapeutics's accrued research and development expenses changed year-over-year?
Bicara Therapeutics's accrued research and development expenses increased by 156.2% year-over-year, from $5.28M to $13.52M.
What is the long-term trend for Bicara Therapeutics's accrued research and development expenses?
Over 2 years (2023 to 2025), Bicara Therapeutics's accrued research and development expenses has grown at a 47.2% compound annual growth rate (CAGR), from $6.04M to $13.09M.